• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体KP.2和KP.3的出现引发担忧：我们该怎么办？

Emergence of SARS-CoV-2 variants KP.2 and KP.3 sparks concerns: What should we do?

作者信息

Shanmugaraj Balamurugan

机构信息

Department of Biotechnology Karpagam Academy of Higher Education Coimbatore India.

出版信息

Health Care Sci. 2024 Aug 6;3(4):211-214. doi: 10.1002/hcs2.110. eCollection 2024 Aug.

DOI:10.1002/hcs2.110
PMID:39220429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11362655/
Abstract

SARS-CoV-2 continues to evolve and circulate globally. In recent weeks, variants such as KP.2 and KP.3 have been rapidly increasing in many countries. Prevention strategies such as receiving updated COVID-19 vaccines, wearing masks when recommended, washing hands frequently, getting tested if symptoms appear, and staying home when sick can help protect individuals and others from COVID-19.

摘要

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）持续在全球演变和传播。最近几周，诸如KP.2和KP.3等变体在许多国家迅速增加。采取如接种最新的2019冠状病毒病（COVID-19）疫苗、在建议时佩戴口罩、经常洗手、出现症状时进行检测以及生病时居家等预防策略，有助于保护个人和他人免受COVID-19感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/081c/11362655/a6304b56c8d1/HCS2-3-211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/081c/11362655/a6304b56c8d1/HCS2-3-211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/081c/11362655/a6304b56c8d1/HCS2-3-211-g002.jpg

相似文献

1
Emergence of SARS-CoV-2 variants KP.2 and KP.3 sparks concerns: What should we do?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体KP.2和KP.3的出现引发担忧：我们该怎么办？
Health Care Sci. 2024 Aug 6;3(4):211-214. doi: 10.1002/hcs2.110. eCollection 2024 Aug.
2
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
3
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.SARS-CoV-2 变异株特异性复制 RNA 疫苗可预防同源关切变异株挑战后的疾病。
Elife. 2022 Feb 22;11:e75537. doi: 10.7554/eLife.75537.
4
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.原型和 BA.5 蛋白纳米颗粒疫苗可预防叙利亚仓鼠感染奥密克戎 BA.5 变异株。
J Virol. 2024 Mar 19;98(3):e0120623. doi: 10.1128/jvi.01206-23. Epub 2024 Feb 2.
5
The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape.新兴的 FLiRT 变体挑战：大流行格局中的 KP.1.1 和 KP.2。
QJM. 2024 Jul 1;117(7):485-487. doi: 10.1093/qjmed/hcae102.
6
Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2.新冠病毒变异株适应性疫苗的有效性及针对奥密克戎BA.1和BA4-5亚型建立群体免疫的能力
Vaccines (Basel). 2023 Dec 10;11(12):1836. doi: 10.3390/vaccines11121836.
7
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性：一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
8
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.新型 COVID-19 变种及其对 SARS-CoV-2 诊断、治疗和疫苗的影响。
Ann Med. 2022 Dec;54(1):524-540. doi: 10.1080/07853890.2022.2031274.
9
Tracking KP.2 SARS-CoV-2 Variant in India and the Clinical Profile of KP.2 Cases in Maharashtra, India.追踪印度的KP.2新冠病毒变异株以及印度马哈拉施特拉邦KP.2病例的临床概况
Cureus. 2024 Aug 3;16(8):e66057. doi: 10.7759/cureus.66057. eCollection 2024 Aug.
10
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.奥密克戎 SARS-CoV-2 新变体：全球流行情况以及生物学和临床特征。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. doi: 10.26355/eurrev_202112_27652.

引用本文的文献

1
Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.马尔堡病毒病的治疗进展：从实验性治疗到疫苗研发
Ann Med Surg (Lond). 2025 Mar 28;87(5):2784-2799. doi: 10.1097/MS9.0000000000003213. eCollection 2025 May.
2
Regional dynamics and mechanisms behind SARS-CoV-2 XDV.1 prevalence in Chongqing via genomic surveillance and molecular insights.通过基因组监测和分子洞察揭示重庆地区新冠病毒XDV.1毒株流行背后的区域动态及机制
Virus Res. 2025 May;355:199562. doi: 10.1016/j.virusres.2025.199562. Epub 2025 Mar 24.

本文引用的文献

1
The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape.新兴的 FLiRT 变体挑战：大流行格局中的 KP.1.1 和 KP.2。
QJM. 2024 Jul 1;117(7):485-487. doi: 10.1093/qjmed/hcae102.
2
Virological characteristics of the SARS-CoV-2 KP.2 variant.严重急性呼吸综合征冠状病毒2型KP.2变体的病毒学特征。
Lancet Infect Dis. 2024 Jul;24(7):e416. doi: 10.1016/S1473-3099(24)00298-6. Epub 2024 May 20.
3
COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020-2021.2020-2021 年 45 个高收入国家德尔塔变异株流行期间的 COVID-19 流行病学
Emerg Infect Dis. 2023 Sep;29(9):1757-1764. doi: 10.3201/eid2909.230142. Epub 2023 Jul 26.
4
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.疫苗的可及性、公平性和正义：COVID-19 疫苗和接种。
BMJ Glob Health. 2023 Jun;8(6). doi: 10.1136/bmjgh-2023-011881.
5
Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection.自然感染和疫苗诱导的免疫对于预防 SARS-CoV-2 感染的效果相当。
J Infect Public Health. 2023 Aug;16(8):1137-1141. doi: 10.1016/j.jiph.2023.05.018. Epub 2023 May 20.
6
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.SARS-CoV-2 变异株的进化：对免疫逃逸、疫苗接种、治疗和诊断策略的影响。
Viruses. 2023 Apr 10;15(4):944. doi: 10.3390/v15040944.
7
Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations.暴发信息基因组报告：可扩展和动态监测 SARS-CoV-2 变体和突变。
Nat Methods. 2023 Apr;20(4):512-522. doi: 10.1038/s41592-023-01769-3. Epub 2023 Feb 23.
8
Lessons Learned from the Lessons Learned in Public Health during the First Years of COVID-19 Pandemic.从 COVID-19 大流行最初几年公共卫生中吸取的经验教训。
Int J Environ Res Public Health. 2023 Jan 18;20(3):1785. doi: 10.3390/ijerph20031785.
9
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学：免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
10
The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England.在英国，SARS-CoV-2 的 Delta 变异株迅速被奥密克戎（B.1.1.529）取代。
Sci Transl Med. 2022 Jul 6;14(652):eabo5395. doi: 10.1126/scitranslmed.abo5395.